[HTML][HTML] The Association of Blood Eosinophils and Neutrophils Expressing Eosinophilic Surface Markers with the Severity and Outcome of COVID-19
J Wang, X Li, J Ren, Y Rao, Y Qiao, L Sun, Y Liang… - Microorganisms, 2024 - mdpi.com
(1) Background: The implication of type 2 (T2) inflammatory response in COVID-19 remains
controversial. This study aimed to evaluate the association of eosinophils, neutrophils …
controversial. This study aimed to evaluate the association of eosinophils, neutrophils …
[HTML][HTML] Biologics in allergology and clinical immunology: Update on therapies for atopic diseases, urticaria, and angioedema and on safety aspects focusing on …
U Jappe, KC Bergmann, F Brinkmann… - Allergologie …, 2024 - pmc.ncbi.nlm.nih.gov
The development of targeted therapies for atopic diseases, urticaria, and angioedema with
biologics is progressing rapidly: New “targets” of clinical-therapeutic relevance have been …
biologics is progressing rapidly: New “targets” of clinical-therapeutic relevance have been …
Booster vaccination normalizes postvaccination immunity in patients with severe asthma
However, unlike the patients with asthma who were being treated with biologics in the study
by Runnstrom et al, 1 similar patients in our study (ie, patients taking a biologic) did not have …
by Runnstrom et al, 1 similar patients in our study (ie, patients taking a biologic) did not have …
Unraveling the influence of Interleukin-5 on eosinophil development: Contribution to a better understanding of precision therapies for severe eosinophilic asthma
G Van Hulst - 2024 - orbi.uliege.be
Eosinophils are key suspects in the pathogenesis of various type 2 immune disorders.
Particularly in type 2 asthma, eosinophils contribute to airway inflammation, bronchial …
Particularly in type 2 asthma, eosinophils contribute to airway inflammation, bronchial …
[CITATION][C] Impact of biologics on the immune response to mRNA COVID-19 vaccination in patients with asthma
SY Liao, B Make, ME Wechsler - Journal of Allergy and Clinical …, 2025 - jacionline.org
REFERENCES 1. Runnstrom MC, Lamothe PA, Faliti CE, Cheedarla N, Moreno A, Suthar
MS, et al. Patients taking benralizumab, dupilumab, or mepolizumab have lower …
MS, et al. Patients taking benralizumab, dupilumab, or mepolizumab have lower …